Objective — to increase survival rates in patients with metastatic brain involvement and to reveal positive and negative prognostic factors. Subjects and methods. In 2007 to 2013, the P.A. Herzen Moscow Oncology Research Institute treated 268 patients with brain metastases. The patients’ mean age was 55.8 years (24 to 81 years). There were metastases of colorectal cancer (7.8%) and lung cancer (34%), melanoma (9.3%), breast cancer (26%), kidney cancer (11%), cancer of other organs (6.7%); the primary focus was not detected in 4.5% of the patients. Solitary metastasis was diagnosed in 164 (61.19%) patients, oligometastases (n=2—3) in 72 (26.87%), and multiple metastases (>3) in 32 (11.94%). Metastatic brain involvement was the only manifestation of a generalized process in 106 (39.55%) patients. Fluorescence diagnosis with Alasens was used to control the radicality of tumor removal in 93 (34.7%) patients. An intraoperative photodynamic therapy session was performed in 66 (24.6%) patients. Metastasis was removed totally and subtotally in 212 (79.1%) and 55 (20.9%) cases, respectively. Results. The follow-up of the patients lasted 3 to 79 months. The median survival was 12 months. Overall survival depended on RPA class, postoperative treatment volume, the histological type of a primary tumor, the number of intracerebral metastases, and the duration of a relapse-free period. Conclusion. Factors, such as the histology of a primary focus, the multiplicity of metastatic involvement, RPA class, and the synchronous pattern of tumor dissemination, influence overall survival. The median overall survival in patients who had received no other therapy options after surgical treatment was only 4 months. When combined treatment (surgery and radiation of the brain) was performed, the median survival was 9—10.5 months (depending on a radiation mode). With drug therapy, that was 11 months. With combination treatment, the survival rates were highest (12 months).